2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Antiviral Treatment for Mild to Moderate COVID-19 in Adults

作者：Amy Hirsch Shumaker, Adarsh Bhimraj, Roger Bedimo, Vincent Chi‐Chung Cheng, Kara W Chew, Eric S Daar, David V. Glidden, Robert W. Shafer, Phyllis C. Tien, Lindsey R Baden, Kelly Cawcutt, Kathleen Chiotos, Amy Dzierba, Erica Hardy, S.A. Johnson, Arthur Y Kim, Christine E. MacBrayne, Greg S. Martin, Nandita R. Nadig, Mari Nakamura, Carlos R. Oliveira, Jeffrey C Pearson, Laura Riley, Shmuel Shoham, Pablo Tebas, Zach Willis, Joshua Wolf, Jennifer Loveless, Rebecca L. Morgan, Yngve Falck-Ytter, Rajesh T. Gandhi · 发表于：Clinical Infectious Diseases · 年份：2026 · DOI：10.1093/cid/ciaf680 · 被引用次数：2 · 研究领域：COVID-19 Clinical Research Studies、SARS-CoV-2 and COVID-19 Research、Respiratory viral infections research

This article provides a focused update to the clinical practice guideline on the treatment and management of people with COVID-19, developed by the Infectious Diseases Society of America. The guideline panel presents 9 updated recommendations on the use of nirmatrelvir/ritonavir, remdesivir, and molnupiravir, in adults with mild to moderate COVID-19. The recommendations are based on evidence derived from a systematic literature review and adhere to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. The panel also provides a section on how to apply these recommendations, including an algorithm on the selection of antivirals.